183 related articles for article (PubMed ID: 16546682)
1. Construction of a novel chimera consisting of a chelator-containing Tat peptide conjugated to a morpholino antisense oligomer for technetium-99m labeling and accelerating cellular kinetics.
Zhang YM; Tung CH; He J; Liu N; Yanachkov I; Liu G; Rusckowski M; Vanderheyden JL
Nucl Med Biol; 2006 Feb; 33(2):263-9. PubMed ID: 16546682
[TBL] [Abstract][Full Text] [Related]
2. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.
Liu G; He J; Dou S; Gupta S; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1115-23. PubMed ID: 16133391
[TBL] [Abstract][Full Text] [Related]
3. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
[TBL] [Abstract][Full Text] [Related]
4. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.
Wang Y; Nakamura K; Liu X; Kitamura N; Kubo A; Hnatowich DJ
Bioconjug Chem; 2007; 18(4):1338-43. PubMed ID: 17605463
[TBL] [Abstract][Full Text] [Related]
5. In vitro investigations of tumor targeting with (99m)Tc-labeled antisense DNA.
Zhang YM; Wang Y; Liu N; Zhu ZH; Rusckowski M; Hnatowich DJ
J Nucl Med; 2001 Nov; 42(11):1660-9. PubMed ID: 11696636
[TBL] [Abstract][Full Text] [Related]
6. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In.
Liu X; Wang Y; Nakamura K; Kawauchi S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
J Nucl Med; 2009 Apr; 50(4):582-90. PubMed ID: 19289423
[TBL] [Abstract][Full Text] [Related]
7. (99m)Tc-MORF oligomers specific for bacterial ribosomal RNA as potential specific infection imaging agents.
Chen L; Wang Y; Cheng D; Liu X; Dou S; Liu G; Hnatowich DJ; Rusckowski M
Bioorg Med Chem; 2013 Nov; 21(21):6523-30. PubMed ID: 24054488
[TBL] [Abstract][Full Text] [Related]
8. Improving the labeling of S-acetyl NHS-MAG(3)-conjugated morpholino oligomers.
Liu G; Zhang S; He J; Zhu Z; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2002; 13(4):893-7. PubMed ID: 12121147
[TBL] [Abstract][Full Text] [Related]
9. Uptake kinetics of 99mTc-MAG3-antisense oligonucleotide to PCNA and effect on gene expression in vascular smooth muscle cells.
Zhang YR; Zhang YX; Cao W; Lan XL
J Nucl Med; 2005 Jun; 46(6):1052-8. PubMed ID: 15937319
[TBL] [Abstract][Full Text] [Related]
10. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.
Liu G; He J; Dou S; Gupta S; Vanderheyden JL; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):417-24. PubMed ID: 14691611
[TBL] [Abstract][Full Text] [Related]
11. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.
Liu G; Mang'era K; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
J Nucl Med; 2002 Mar; 43(3):384-91. PubMed ID: 11884499
[TBL] [Abstract][Full Text] [Related]
12. Initial observations of 99mTc labelled locked nucleic acids for antisense targeting.
Zhang Y; He J; Liu G; Venderheyden JL; Gupta S; Rusckowski M; Hnatowich DJ
Nucl Med Commun; 2004 Nov; 25(11):1113-8. PubMed ID: 15577590
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores.
Decristoforo C; Santos I; Pietzsch HJ; Kuenstler JU; Duatti A; Smith CJ; Rey A; Alberto R; Von Guggenberg E; Haubner R
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):33-41. PubMed ID: 17372571
[TBL] [Abstract][Full Text] [Related]
14. Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy.
Polyakov V; Sharma V; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
Bioconjug Chem; 2000; 11(6):762-71. PubMed ID: 11087323
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc.
Liu CB; Liu GZ; Liu N; Zhang YM; He J; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2003 Feb; 30(2):207-14. PubMed ID: 12623121
[TBL] [Abstract][Full Text] [Related]
16. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA.
Zhang YM; Liu N; Zhu ZH; Rusckowski M; Hnatowich DJ
Eur J Nucl Med; 2000 Nov; 27(11):1700-7. PubMed ID: 11105827
[TBL] [Abstract][Full Text] [Related]
17. Antisense targeting of p-glycoprotein expression in tissue culture.
Nakamura K; Kubo A; Hnatowich DJ
J Nucl Med; 2005 Mar; 46(3):509-13. PubMed ID: 15750166
[TBL] [Abstract][Full Text] [Related]
18. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide.
Maresca KP; Marquis JC; Hillier SM; Lu G; Femia FJ; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
Bioconjug Chem; 2010 Jun; 21(6):1032-42. PubMed ID: 20402463
[TBL] [Abstract][Full Text] [Related]
19. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles.
Wang Y; Liu X; Nakamura K; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2009 Oct; 24(5):573-8. PubMed ID: 19877887
[TBL] [Abstract][Full Text] [Related]
20. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.
Liu G; Dou S; He J; Liu X; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):237-46. PubMed ID: 17021815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
